ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Oncology and Hematology News and Journal Articles

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise

Phillip L. Palmbos, MD, PhD, and Maha H. Hussain, MD
This article will review how PARP inhibitors function as a class, review the molecular features that sensitize cancer cells to this therapy, and discuss the data supporting its potential for patients with prostate cancer.

Recent Content

A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.

The accuracy of interpreting a breast cancer screening mammogram is not diminished when clinicians evaluate more mammograms in a single session.

A 5-year analysis of the DASISION trial showed that dasatinib continued to offer better responses than imatinib in patients with chronic myeloid leukemia.

Gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure in young women with lymphoma.

This slide show presents tricks for surviving and thriving at the ASCO Annual Meeting in Chicago. Everything from transportation, McCormick Place, planning your days, using social media, which sessions to attend, how to network, where to eat, and how to be a tourist in Chicago.

Women who do not engage in regular physical activity have an increased risk of developing cervical cancer, according to a new study

Grade 3/4 neutropenia is a common adverse event experienced by patients undergoing treatment for relapsed, refractory multiple myeloma with lenalidomide and dexamethasone, a new study has found.

By clicking Accept, you agree to become a member of the UBM Medica Community.